466 related articles for article (PubMed ID: 28724379)
1. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Broecker-Preuss M; Becher-Boveleth N; Bockisch A; Dührsen U; Müller S
J Transl Med; 2017 Jul; 15(1):158. PubMed ID: 28724379
[TBL] [Abstract][Full Text] [Related]
2. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
4. EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.
Jung KH; Lee EJ; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
PLoS One; 2019; 14(9):e0221294. PubMed ID: 31532771
[TBL] [Abstract][Full Text] [Related]
5. Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC.
Pang YY; Wang T; Chen FY; Wu YL; Shao X; Xiao F; Huang HH; Zhong H; Zhong JH
Leuk Lymphoma; 2015 Jun; 56(6):1821-30. PubMed ID: 25219592
[TBL] [Abstract][Full Text] [Related]
6. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
Fleming IN; Andriu A; Smith TA
Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of c-MYC transcription factor modulates the expression of glycolytic and glutaminolytic enzymes in FaDu hypopharyngeal carcinoma cells.
Kleszcz R; Paluszczak J; Krajka-Kuźniak V; Baer-Dubowska W
Adv Clin Exp Med; 2018 Jun; 27(6):735-742. PubMed ID: 29790697
[TBL] [Abstract][Full Text] [Related]
8. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
9. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
10. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
Liu Y; Zhao Y; Guo L
Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689
[TBL] [Abstract][Full Text] [Related]
11. Silencing of FGF6 hampers aerobic glycolysis and angiogenesis in bladder cancer by regulating PI3K/Akt and MAPK signaling pathways.
Zhi Y; Cai C; Xu T; Sun F; Wang KP; Ji Z; Pei Y; Geng S; Wang H
J Biochem Mol Toxicol; 2023 Aug; 37(8):e23399. PubMed ID: 37345681
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas.
Faber AC; Dufort FJ; Blair D; Wagner D; Roberts MF; Chiles TC
Biochem Pharmacol; 2006 Nov; 72(10):1246-56. PubMed ID: 16979140
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
14. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma.
Zhuo B; Li Y; Li Z; Qin H; Sun Q; Zhang F; Shen Y; Shi Y; Wang R
Biochem Biophys Res Commun; 2015 Aug; 464(2):401-6. PubMed ID: 26116768
[TBL] [Abstract][Full Text] [Related]
16. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
18. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
19. Arginine ADP-ribosyltransferase 1 Regulates Glycolysis in Colorectal Cancer via the PI3K/AKT/HIF1α Pathway.
Long WB; Pu X; Tang Y; Li M; Liu Y; She Q; Wang YL; Guo QX
Curr Med Sci; 2022 Aug; 42(4):733-741. PubMed ID: 35798928
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein.
Hong SY; Yu FX; Luo Y; Hagen T
Cell Signal; 2016 May; 28(5):377-383. PubMed ID: 26826652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
